Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 67
- Registration Number
- NCT00699504
- Locations
- 🇺🇸
Charles River Clinical Services NW, Tacoma, Washington, United States
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 37
- Registration Number
- NCT00666328
- Locations
- 🇺🇸
Maine Medical Center, Portland, Massachusetts, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇩🇪Universitatsklinikum Heidelberg, Heidelberg, Germany
Bivalirudin as a Procedural Anticoagulant in Pediatrics
- Conditions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 110
- Registration Number
- NCT00503126
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 5364
- Registration Number
- NCT00385138
- Locations
- 🇺🇸
Innovis Health, Fargo, North Dakota, United States
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 131
- Registration Number
- NCT00369837
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Good Samaritan Hospital, Baltimore, Maryland, United States
🇺🇸Providence Heart & Vascular Institute, d/b/a Providence St. Vincent Medical Center, Portland, Oregon, United States
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
- Conditions
- Interventions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 8882
- Registration Number
- NCT00305162
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
- Conditions
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 40
- Registration Number
- NCT00102674
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 739
- Registration Number
- NCT00093912
- Locations
- 🇺🇸
International Heart Institute/St. Patrick Hospital, Missoula, Montana, United States
🇺🇸Mt. Sinai Medical Center, New York, New York, United States
🇺🇸Jackson-Madison County General Hospital, Jackson, Tennessee, United States
Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 739
- Registration Number
- NCT00093925
- Locations
- 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 629
- Registration Number
- NCT00093886
- Locations
- 🇺🇸
Sacred Heart Health System, Pensacola, Florida, United States
🇺🇸New York University Medical Center, New York, New York, United States
🇺🇸Baptist Medical Center, South, Montgomery, Alabama, United States